Angiotensin-Converting Enzyme Inhibitors

Hypertension

Volumn , Issue , 2005, Pages 669-682

  Sica, Domenic A ^a,b   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350101577     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50155-1     Document Type: Chapter

References (168)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289:2560-2572.
2. Sica DA, Gehr TWB Angiotensin converting enzyme inhibitors. Hypertension: A Companion to the Kidney, 1st edition 2000, 599-608. WB Saunders, Philadelphia. S. Oparil, M. Weber (Eds.).
3. Sica DA, Gehr TWB, Frishman WH The renin-angiotensin axis: Angiotensin converting enzyme inhibitors and angiotensin-receptor blockers. Cardiovascular Pharmacotherapeutics, 2nd ed 2003, 131-156. McGraw-Hill, New York. W. Frishman, S. Sonnenblick, D.A. Sica (Eds.).
4. Warner GT, Perry CM Ramipril: A review of its use in the prevention of cardiovascular outcomes. Drugs 2002, 62:1381-1405.
5. White CM Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998, 18:588-599.
6. Cody R Optimizing ACE inhibitor therapy of congestive heart failure: Insights from pharmacodynamic studies. Clin Pharmacokinet 1993, 24:59-70.
7. Chalmers D, Whitehead A, Lawson DH Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 1992, 34:215-223.
8. Sica DA Angiotensin converting enzyme inhibitors: Fosinopril. Cardiovascular Drug Therapy, 2nd ed 1996, 801-809. WB Saunders, Philadelphia. F. Messerli (Ed.).
9. Brockmeier D Tight binding influencing the future of pharmacokinetics. Meth Find Exp Clin Pharmacol 1998, 20:505-516.
10. Reid JL From kinetics to dynamics: Are there differences between ACE inhibitors?. Eur Heart J 1997, 18(Suppl E):E14-E18.
11. Hoyer J, Schulte K-L, Lenz T Clinical pharmacokinetics of angiotensin converting enzyme inhibitors in renal failure. Clin Pharmacokinet 1993, 24:230-254.
12. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(Suppl 9):1L-20L.
13. Ebihara A, Fujimura A Metabolites of antihypertensive drugs: An updated review of their clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991, 21:331-343.
14. Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991, 49:457-467.
15. Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994, 23(Suppl 4):S50-S59.
16. Brunner-La Rocca HP, Weilenmann D, Kiowski W, et al. Plasma levels of enalaprilat in chronic therapy of heart failure: Relationship to adverse events. J Pharmacol Exp Ther 1999, 289:565-571.
17. Brown NJ, Vaughn DE Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
18. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989, 7(Suppl):S11-S16.
19. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
20. Leonetti G, Cuspidi C Choosing the right ACE inhibitor. A guide to selection. Drugs 1995, 49:516-535.
21. Zeitz CJ, Campbell DJ, Horowitz JD Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension 2003, 41:482-487.
22. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003, 349:2224-2232.
23. The SOLVD investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
24. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
25. Sica DA The HOPE Study: ACE inhibitors: Are their benefits a class effect or do individual agents differ?. Curr Opin Nephrol Hypertens 2001, 10:597-601.
26. Segura J, Christiansen H, Campo C, et al. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?. Curr Hypertens Rep 2003, 5:426-429.
27. Wilson Tang WH, Vagelos RH, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70-78.
28. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999, 100:2312-2318.
29. Massie B Neurohormonal blockade in chronic heart failure: How much is enough? Can there be too much?. J Am Coll Cardiol 2002, 39:79-82.
30. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70-78.
31. Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998, 32:1811-1818.
32. Carretero OA, Scicli AG The kallikrein-kinin system as a regulator of cardiovascular and renal function. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed 1995, 983-999. Raven Press, Ltd, New York. B.M. Brenner, J.H. Laragh (Eds.).
33. Urata H, Nishimura H, Ganten D Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996, 9:277-284.
34. Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001, 37:1056-1061.
35. Ennezat PV, Berlowitz M, Sonnenblick EH, et al. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000, 2:258-262.
36. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15:276-282.
37. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
38. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998, 339:1285-1292.
39. Tom B, Dendorfer A, Danser AH Bradykinin, angiotensin (1-7), and ACE inhibitors: How do they interact?. Int J Biochem Cell Biol 2003, 35:792-801.
40. Rodriguez-Garcia JL, Villa E, Serrano M, et al. Prostacyclin: Its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism. Blood Press 1999, 8:279-284.
41. Johnson AG NSAIDs and increased blood pressure: What is the clinical significance?. Drug Saf 1997, 17:277-289.
42. Morgan T, Anderson A The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003, 5:53-57.
43. Nawarskas JJ, Townsend RR, Cirigliano MD, et al. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999, 12:784-789.
44. Zanchetti A, Hansson L, Leonetti G, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002, 20:1015-1022.
45. Cleland JG, John J, Houghton T Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?. Curr Opin Nephrol Hypertens 2001, 10:625-631.
46. Lang CC, Stein M, He HB, et al. Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects. Clin Pharmacol Ther 1996, 59:668-674.
47. Ranadive SA, Chen AX, Serajuddin AT Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res 1992, 9:1480-1486.
48. Fagard R, Amery A, Reybrouck T, et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980, 46:295-300.
49. Slavachevsky I, Rachmani R, Levi Z, et al. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients. J Am Geriatr Soc 2000, 48:807-810.
50. Vanhoutte PM Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998, 19(Suppl):J7-J15.
51. Schiffrin EL Effects of antihypertensive drugs on vascular remodeling: Do they predict outcome in response to antihypertensive therapy?. Curr Opin Nephrol Hypertens 2001, 10:617-624.
52. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2002, 348:583-592.
53. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:1981-1997. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Group.
54. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
55. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
56. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328:914-921.
57. Li X, Du Y, Du Y, et al. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003, 8:25-30.
58. Smith RD, Franklin SS Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985, 79(Suppl 3C):14-23.
59. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH Effect of aging on plasma renin and aldosterone in normal man. Kidney Int 1975, 8:325-333.
60. Israili ZH, Hall WD ACE Inhibitors: Differential use in elderly patients with hypertension. Drugs Aging 1995, 7:355-371.
61. Omboni S, Fogari R, Palatini P, et al. Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect. Evidence from the Sample Study. Hypertension 1998, 32:424-429.
62. Morgan TO, Morgan O, Anderson A Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Clin Exp Pharmacol Physiol 1995, 22:778-780.
63. Sica DA, Gehr TWB Dose-response relationship and dose adjustments. Hypertension Primer, 2nd ed 1999, 342-344. Baltimore, Lippincott Williams & Wilkins.
64. Elung-Jensen T, Heisterberg J, Kamper AL, et al. Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Br J Clin Pharmacol 2003, 55:139-146.
65. Sica DA Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002, 62:443-462.
66. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003, 326:427-434.
67. Docherty A, Dunn FG Treatment of hypertensive patients with coexisting coronary arterial disease. Curr Opin Cardiol 2003, 18:268-271.
68. Black HR, Sollins JS, Garofalo JL The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo-controlled study. Am J Hypertens 2000, 13:468-474.
69. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997, 79:431-435.
70. DeQuattro V, Lee D Fixed-dose combination therapy with tran-dolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997, 10(Suppl 2):138S-145S.
71. Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: A placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001, 15:495-498.
72. Sica DA Calcium-channel blocker edema: Can it be resolved?. J Clin Hypertens 2003, 5:291-294.
73. Zuccala G, Onder G, Pedone C, et al. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors. Eur J Clin Pharmacol 2003, 58:695-699.
74. Sica DA Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: Its role in clinical practice: Practical aspects of combination therapy with angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. J Clin Hypertens 2003, 5:414-420.
75. Taylor AA Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?. Curr Opin Nephrol Hypertens 2001, 10:643-648.
76. Pogatsa-Murray G, Varga L, Varga A, et al. Changes in left ventricular mass during treatment with minoxidil and cilazapril in hypertensive patients with left ventricular hypertrophy. J Hum Hypertens 1997, 11:149-156.
77. Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995, 155:2217-2223.
78. Sica DA Dosage considerations with perindopril for hypertension. Am J Cardiol 2001, 88(Suppl 1):13-18.
79. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. Circulation 1997, 95:2007-2014.
80. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345-352.
81. Fox KM European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
82. Daly P, Mettauer B, Rouleau JL, et al. Lack of reflex increase in myocardial sympathetic tone after captopril: Potential antianginal mechanism. Circulation 1985, 71:317-325.
83. Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003, 42:2049-2059.
84. Schiffrin EL Effect of antihypertensive treatment on small artery remodeling in hypertension. Can J Physiol Pharmacol 2003, 81:168-176.
85. Walters MR, Bolster A, Dyker AG, et al. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 2001, 32:473-478.
86. Regensteiner JG, Hiatt WR Current medical therapies for patients with peripheral arterial disease: A critical review. Am J Med 2002, 112:49-57.
87. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004, 25:17-24.
88. Position statement: Hypertension management in adults with diabetes. Diabetes Care 2004, 27:S65-S67.
89. Lithell HO, Pollare T, Berne C Insulin sensitivity in newly detected hypertensive patients: Influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardio vasc Pharmacol 1990, 15(Suppl 5):S46-S52.
90. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. J Am Med Assoc 2001, 286:1882-1885.
91. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
92. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002, 162:1636-1643.
93. Yu HT Progression of chronic renal failure. Arch Intern Med 2003, 163:1417-1429.
94. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003, 139:901-906.
95. Donnelly R, Yeung JM, Manning G Microalbuminuria: A common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens 2003, 21(Suppl 1):S7-S12.
96. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: The kidney early evaluation program (KEEP). Am J Kidney Dis 2003, 42:22-35.
97. Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 2003, 290:3014-3101.
98. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
99. Laverman GD, Remuzzi G, Ruggenenti P ACE inhibition versus angiotensin receptor blockade: Which is better for renal and cardiovascular protection?. J Am Soc Nephrol 2004, 15(Suppl 1):S64-S70.
100. Laverman GD, de Zeeuw D, Navis G Between-patient differences in the renal response to renin-angiotensin system intervention: Clue to optimising renoprotective therapy?. J Renin Angiotensin Aldosterone Syst 2002, 3:205-213.
101. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
102. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 1994, 45:S150-S155.
103. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group. J Am Med Assoc 1994, 271:275-279.
104. Uhle BU, Whitworth JA, Shahinfar S, et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kidney Dis 1996, 27:489-495.
105. Giatras I, Lau J, Levey As, et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997, 127:337-347.
106. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001, 285:2719-2728.
107. Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the captopril study. Am J Kidney Dis 1999, 34:308-314.
108. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999, 34:809-817.
109. Estacio RO, Esler A, Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
110. Estacio R, Jeffers R, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54-B64.
111. Jafar T, Schmid C, Landa M, et al. The effect of angiotensin-converting-enzyme inhibitors on the progression of non-diabetic renal disease: A pooled analysis of individual patient data from 11 randomized controlled trials. Ann Intern Med 2001, 135:73-87.
112. Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35:1155-1165.
113. Sica DA Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992, 20(Suppl 10):S13-S20.
114. Jafar TH, Stark PC, Schmid CH, et al. Angiotensin-converting enzyme inhibition and progression of renal disease: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
115. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: Results ofthe HOPE randomized study. J Am Soc Nephrol 2003, 14:641-647.
116. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIAB-HYCAR study). Br Med J 2004, 328:495.
117. Laverman G, Ruggenenti P, Remuzzi G Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. Curr Hypertens Rep 2003, 5:364-367.
118. Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003, 107:586-592.
119. Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
120. Apperloo AJ, de Zeeuw D, de Jong PE A short-term antihyper-tensive-treatment induced drop in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997, 51:793-797.
121. Sica DA Assessment of the role of ACE inhibitors in the elderly. Hypertension in the Elderly 2005, NJ, Humana Press, Inc., Totowa. M. Prisant (Ed.).
122. Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989, 36:272-279.
123. Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998, 13:1682-1685.
124. Gansevoort RT, de Zeeuw D, de Jong PE Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease. Nephrol Dial Transplant 1995, 10:497-504.
125. Buter H, Hemmelder MH, van Paassen P, et al. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?. Nephrol Dial Transplant 1997, 12(Suppl 2):53-56.
126. Ueda S, Elliott, Morton JJ, et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995, 25:1266-1269.
127. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992, 359:641-644.
128. Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme. Observational follow-up study. Br Med J 1996, 313:591-594.
129. Rudnicki M, Mayer G Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease: Pathophysiological considerations. Pharmacogenomics 2003, 4:153-162.
130. Garg R, Yusuf S Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995, 273:1450-1456. for the Collaborative Group on ACE Inhibitor Trials.
131. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
132. Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: The medicare health care quality improvement program. Arch Intern Med 2003, 163:1430-1439.
133. Megarry M, Sapsford R, Hall AS, et al. Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction?. Drugs 1997, 54(Supplement 5):48-58.
134. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic review of individual data from 100,000 patients in randomised trials. Circulation 1998, 97:2202-2212.
135. Liu P, Arnold JM, Belenkie I, et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003, 19:347-356.
136. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001, 104:2996-3007.
137. Massie B Neurohormonal blockade in chronic heart failure: How much is enough? Can there be too much?. J Am Coll Cardiol 2002, 39:79-82.
138. Remme WJ Effect of ACE inhibition on neurohormones. Eur Heart J 1998, 19(Supplement J):J16-J23.
139. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 2003, 361:1077-1083.
140. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001, 104:1985-1991.
141. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003, 41:2029-2035.
142. Agusti A, Bonet S, Arnau JM, et al. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction: Meta-analysis of randomised clinical trials. Drug Saf 2003, 26:895-908.
143. Bungard TJ, McAlister FA, Johnson JA, et al. Underutilization of ACE inhibitors in patients with congestive heart failure. Drugs 2001, 61:2021-2033.
144. Chen YT, Wang Y, Radford MJ, et al. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001, 141:410-417.
145. Schwartz JS, Wang YR, Cleland JG, et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: An economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Am J Manag Care 2003, 9:417-424.
146. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999, 100:1016-1030.
147. Naccarella F, Naccarelli GV, Maranga SS, et al. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr Opin Cardiol 2002, 17:6-18.
148. Turnbull F Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
149. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
150. Anderson C Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key. Stroke 2003, 34:1333-1334.
151. Bath P Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key. Stroke 2003, 34:1334-1335.
152. Davis SM, Donnan GA Blood pressure reduction and ACE inhibition in secondary stroke prevention: Mechanism uncertain. Stroke 2003, 34:1335-1336.
153. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2002, 324:1-5.
154. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32:280-299.
155. Textor SC Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997, 17:67-76.
156. Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003, 26:983-989.
157. Textor SC, Bravo EL, Fouad FM, et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982, 73:719-725.
158. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 2003, 289:1652-1658.
159. Cruz CS, Cruz AA, Marcilio de Souza CA Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003, 18:1814-1819.
160. Israili ZH, Hall WD Cough and angioneurotic associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234-242.
161. Chalmers D, Dombey SL, Lawson DH Post-marketing surveillance of captopril (for hypertension): A preliminary report. Br J Clin Pharmacol 1987, 24:343-349.
162. Onder G, Pahor M, Gambassi G, et al. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: Results from the Italian group of pharmacoepidemiology in the elderly. Cephalalgia 2003, 23:901-906.
163. Gibbs CR, Lip GYH, Beevers DG Angioedema due to ACE inhibitors: Increased risk in patients of African origin. Br J Clin Pharmacol 1999, 48:861-865.
164. Gregory KW, Davis RC Images in clinical medicine: Angioedema of the intestine. N Engl J Med 1996, 334:1641.
165. Cheng RM, Mamdani M, Jackevicius CA, et al. Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother 2003, 37:994-998.
166. Sica DA, Gehr TWB The pharmacokinetics and pharmacodynamics of angiotensin receptor blockers in end-stage renal disease. J Renin-Angio Aldo Sys 2002, 3:247-254.
167. Trivedi H, Lal SM A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Ren Fail 2003, 25:77-86.
168. Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: A prospective randomised trial. Lancet 2002, 359:663-666.